Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.56 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632114 | 0.91 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL4844008 | 0.86 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18627151 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1713370 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19867620 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1633897 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19867633 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14307351 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL31070273 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29364802 | 0.81 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-7932379-B2 | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1603/4885 |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1603/4885 |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.